Serial #79415190
LIVE

Serial Number

79415190

Owner

AAVantgarde Bio Srl

Attorney

Scott J. Major

Filing Date

Jun 7, 2024

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79415190 Trademark

Serial Number: 79415190 • Registration: 8200233

Serial #79415190 is a trademark filed by AAVantgarde Bio Srl on June 7, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

AAVantgarde Bio Srl (2 trademarks)

8 Via Vincenzo Gioberti
Milan 20123 , IT

Entity Type: 99

Trademark Details

Filing Date

June 7, 2024

Registration Date

April 7, 2026

Published for Opposition

February 17, 2026

Goods & Services

Custom manufacturing of pharmaceuticals and pharmaceuticals processing; custom manufacturing of biotechnological pharmaceuticals and biopharmaceuticals and processing of biotechnological pharmaceuticals and biopharmaceuticals; custom biomanufacturing for others, namely, manufacturing of viral vectors using biological organisms in the manufacturing process; custom manufacturing of pharmaceuticals for gene therapy; pharmaceutical formulation being custom pharmaceutical manufacturing; information, advice and consultancy services relating to the aforementioned services

Scientific and technological services and research or design relating thereto, namely, scientific research in the fields of gene therapy and cell therapy; industrial analysis and research services in the fields of gene therapy and cell therapy; biological and medical product research and development; preclinical and clinical research and development in the fields of gene therapy and cell therapy; gene therapy research; genetic engineering, gene editing, namely, the modification of genetic material in a living organism; genetic medicine, gene therapy and genome editing research, development, analytics, clinical trials and consultancy relating thereto; biochemical assay development and performance, namely, monitoring of patients prior and subsequent to gene therapy; diagnostics development and performance, namely, monitoring of patients prior and subsequent to gene therapy; biomarker identification, namely, detection and measurement of biological properties or molecules in the body; manufacturing analytics and manufacturing process design, development and optimisation; scientific research and development services and clinical trials services in relation to pharmaceutical preparations and substances for the treatment of disorders relating to the eye and ear, biotechnological preparations for the treatment of disorders relating to the eye and ear, preparations for gene therapy and cell therapy for the treatment of disorders relating to the eye and ear and genetic medicines for the treatment of disorders relating to the eye and ear; information, advice and consultancy services relating to the aforementioned services

Medical services; medical services in the field of genetic or inherited or non-infectious diseases or disorders; medical services in the field of gene therapy or genetic medicine; medical services in the field of gene therapy for ophthalmological diseases and disorders, blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, renal and kidney disorders, hepatological disorders, or nervous system disorders; medical services, namely, gene and nucleic acid delivery and modification for therapeutic purposes in the fields of gene therapy and cell therapy; medical care and medical analysis services relating to the treatment of patients with gene therapy; medical advisory services in the field of gene therapy; provision of medical information relating to gene therapy and genetic medicine via a website; advisory, consultancy and information services relating to the treatment, relief and/or prevention of eye and ear disease, single gene disorders, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders; information, advice and consultancy services relating to the aforementioned services

Medical and veterinary preparations for therapeutic purposes, namely, pharmaceutical preparations for treatment of genetic diseases; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceuticals for the delivery of genes to cells, all for medical purposes; chemical preparations for medical purposes, namely, for use in gene therapy and cell therapy; biologic preparations for medical purposes, namely, for use in gene therapy and cell therapy; biologic preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for medical purposes, namely, adeno-associated viral preparations; pharmaceutical preparations in the nature of adeno-associated viral gene therapy preparations; pharmaceutical preparations and substances for the treatment of ocular and otological disorders; biotechnological preparations for the treatment of ocular and otological disorders; pharmaceutical preparations for gene therapy and cell therapy for the treatment of ocular and otological disorders; genetic medicines for the treatment of ocular and otological disorders; biologic preparations for use in the treatment of ophthalmological diseases and disorders; biologic preparations for use in the treatment of blinding and deafness diseases and disorders; biologic preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders; gene therapy preparations for use in the treatment of ophthalmological diseases and disorders; gene therapy preparations for use in the treatment of blinding and deafness diseases and disorders; gene therapy preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders

Medical and surgical apparatus and instruments for use in gene therapy and cell therapy; medical devices for use in gene therapy and cell therapy; apparatus and instruments for the administration of gene therapy products, namely, dosage dispensers for administering medicine; ophthalmic surgery devices and instruments; veterinary apparatus and instruments for use in gene therapy and cell therapy; cannulae; needles for surgical and medical purposes; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof in the nature of dosage dispensers for administering medicine to patients; apparatus and instruments for performing eye surgery; ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic procedures, including surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; medical apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; medical apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 7, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 7, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 17, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 17, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 11, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 23, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 23, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 23, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 23, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 23, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 18, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 18, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 18, 2025 TROA
REFUSAL PROCESSED BY IB
Nov 30, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 9, 2025 RFCS
REFUSAL PROCESSED BY MPU
Nov 9, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 20, 2025 RFCR
NON-FINAL ACTION WRITTEN
Sep 19, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 10, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 9, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 9, 2025 NWOS
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Sep 2, 2025 CORR
CORRECTION TRANSACTION RECEIVED FROM IB
Mar 21, 2025 CRCV
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 23, 2025 REPR